Live Stock Coverage: It Seems Synergy Pharmaceuticals Inc Will Go Down. Have Another Big Decline

Live Stock Coverage: It Seems Synergy Pharmaceuticals Inc Will Go Down. Have Another Big Decline

The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! About 1.16M shares traded hands. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 55.33% since March 4, 2016 and is uptrending. It has outperformed by 47.29% the S&P500.
The move comes after 9 months negative chart setup for the $904.51M company. It was reported on Oct, 7 by Barchart.com. We have $4.94 PT which if reached, will make NASDAQ:SGYP worth $54.27M less.

Analysts await Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to report earnings on November, 14. They expect $-0.22 EPS, up 4.35% or $0.01 from last year’s $-0.23 per share. After $-0.23 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -4.35% EPS growth.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Ratings Coverage

Out of 5 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Synergy Pharmaceuticals has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned “Buy” rating by Rodman & Renshaw on Monday, May 9. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned “Buy” rating by Rodman & Renshaw on Monday, March 21. The firm has “Buy” rating by BTIG Research given on Tuesday, August 25. On Thursday, October 29 the stock rating was reinitiated by Roth Capital with “”. Citigroup maintained the stock with “Neutral” rating in Wednesday, March 16 report. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) earned “Buy” rating by TH Capital on Thursday, October 29. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, October 1 report. As per Friday, December 18, the company rating was downgraded by Citigroup.

According to Zacks Investment Research, “Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.”

Insitutional Activity: The institutional sentiment increased to 1.61 in Q2 2016. Its up 0.55, from 1.06 in 2016Q1. The ratio is positive, as 16 funds sold all Synergy Pharmaceuticals Inc shares owned while 28 reduced positions. 25 funds bought stakes while 46 increased positions. They now own 99.69 million shares or 58.37% more from 62.94 million shares in 2016Q1.
Raymond James holds 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 19,838 shares. Bank & Trust Of Montreal Can, a Ontario – Canada-based fund reported 33,103 shares. Moreover, Credit Suisse Ag has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 195,140 shares. Bank & Trust Of America Corporation De has invested 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Nationwide Fund Advsr reported 118,459 shares or 0% of all its holdings. The Georgia-based Invesco Ltd has invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Wall Street Assocs last reported 269,300 shares in the company. Moreover, Tower Research Cap Ltd Llc (Trc) has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 139 shares. State Street accumulated 0% or 5.18M shares. Moreover, Blackrock Mgmt Ltd Limited Liability Company has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 704,495 shares. Secor Advsr Limited Partnership has invested 0.07% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Mycio Wealth Prtn Ltd Co holds 370 shares or 0% of its portfolio. The California-based Blackrock Institutional Tru Na has invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Moreover, Cambridge Rech Advisors Inc has 0.02% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 199,975 shares. Wells Fargo Mn has invested 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP).

Insider Transactions: Since September 16, 2016, the stock had 0 insider purchases, and 3 sales for $19.81 million net activity. BRANCACCIO JOHN P also sold $14,504 worth of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) on Monday, September 19. PAULSON & CO. INC. also sold $19.49 million worth of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares.

More news for Synergy Pharmaceuticals Inc (NASDAQ:SGYP) were recently published by: Seekingalpha.com, which released: “Synergy Pharmaceuticals Getting Closer To ‘Go Time'” on October 05, 2016. Businesswire.com‘s article titled: “Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at …” and published on September 28, 2016 is yet another important article.

SGYP Company Profile

Synergy Pharmaceuticals Inc. (Synergy), incorporated on February 11, 1992, is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment